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ACCEPTED MANUSCRIPTAsthma, for the vast majority of children, is more of an inconvenience than a serious condition; 
controlled relatively easily with low dose inhaled corticosteroids (ICS) plus or minus long acting 
beta-agonists or leukotriene receptor antagonists. For a small minority this is not the case and 
asthma is a severe disease that causes major morbidity that can include severe exacerbations 
requiring hospitalization, loss of lung function, social isolation and behavioural problems (1). The 
definition of severe asthma in children varies but generally includes persistent symptoms and/or 
exacerbations despite being prescribed high doses of ICS and other therapies that may include oral 
steroids and biologicals (2). A number of phenotypes contribute to severe asthma in children, 
including poor medication adherence, difficult to treat asthma and steroid resistant asthma (2,3). 
Various attempts have been made to distinguish between children with difficult to treat and steroid 
resistant asthma using measures of asthma control, pulmonary physiology and pulmonary 
inflammation with little consensus (2, 4-6). Major clinical advantage would come from being able 
predict reliably which children with severe asthma are unlikely to respond to ICS. Attempts to 
predict risk of steroid resistance have included risk genotypes and haplotypes (7) and assessment of 
cysteine oxidation impaired glucocorticoid receptor function (8). It is fair to say that, at this stage, 
these attempts have identified risk factors but are not sufficiently predictive to guide treatment of 
individual children. 
In the current issue of the journal, Goleva et al. (9) report results of a study examining expression of 
corticosteroid regulated genes in children with asthma to predict steroid resistance. They recruited 
125 children, aged 6 to17 years, with asthma participating in the Inner City Asthma Consortium’s 
Asthma Phenotypes in the Inner City study. A more comprehensive report of clinical aspects of the 
study and of the study population has been published (6). The study by Govea et al. (9) needs to be 
read in conjunction with this previous report as their description of the patient population and flow 
through the study is insufficient (Figure 1). Screening included checking the physician’s asthma 
diagnosis, children’s medication usage and adherence, and asthma control. Children with less than 
50% estimated medication adherence were excluded in an attempt to study true medication 
responses (7). A predefined, computerized algorithm guided asthma therapy at each visit based on 
symptoms, lung function and recent exacerbations. Six months into the study on algorithm-guided 
therapy children were classified as having: difficult-to-control (requiring fluticasone propionate 
(FP) ≥ 500 µg/day ± other treatment on at least 4 visits); easy-to-control (FP ≤100 µg/day; or 
indeterminate (didn’t fall into the other categories). Children were not reclassified during the 
remaining 6 months of the study. 
Goleva et al. (9) reported on 95 of these children (45 difficult-to-control, 31 easy-to-control, 19 
indeterminate) who gave paired blood samples at the first and last study visits, visits 0 and 6, 
respectively. Peripheral blood mononuclear cells were either lysed immediately or after 3 hours 
culture, with or without 10-8M FP. Outcome measures included: expression of mRNA encoding 
glucocorticoid receptor alpha (GRα) and cytochrome P450 Family 24 subfamily A Member 1 
(cyp24a); FP-induced induction of corticosteroid transactivation (FK binding protein 5 [FKBP5]); 
and FP-induced suppression of IL-8 and TNFα. They reported, on grouped data that children with 
difficult-to-treat asthma had significantly lower GRα that those with easy-to-treat asthma at visit 0, 
but not lower than those in the indeterminate group. There was no relationship between GRα 
expression and level of asthma control in the difficult-to-treat group. GRα expression fell over the 
study period in those with easy-to-treat asthma but not in the difficult-to-treat group. Children in the 
easy-to-treat group showed an increase in FP suppression of IL-8 (30%, p=0.04) and TNFα 
(p=0.07) between V0 and V6. No changes in GRα, IL-8 and TNFα were seen in children in the 
other groups. An increase in FP induction of FKBP5 occurred in the difficult-to-treat group between 
V0 and V6.  Again, there were no associations between these data and asthma control levels. The 
authors should be commended for showing individual data points in addition to the group means 
and 95% CI. Examination of these data show marked overlap in individual values for all outcome 












ACCEPTED MANUSCRIPTGoleva et al. (9) suggest that their PBMC analyses could form the basis for future tests to determine 
which children are likely to be steroid resistant. However, their study has several limitations which 
need to be addressed in followup studies before proceeding further. Firstly they focussed on 
expression of only a small proportion of the genes known to be steroid responsive in PBMC, and 
consequently their findings may represent the tip of a much more interesting and informative 
iceberg.  The technology exists to cast the net far wider, and in an unbiased way, employing 
genome wide expression profiling, including utilization of system level approaches that could 
assess steroid effects at the level of gene networks (10)  But before this is contemplated, there are a 
series of more fundamental clinical issues that need to be considered. As outlined above, severe 
asthma, referred to in this study as difficult-to-treat asthma, contains several phenotypes. Children’s 
asthma can be difficult to treat for various reasons, including lack of adherence, poor inhaler 
technique, failure to use a spacer adequately, continued exposure to a poor environment containing 
inflammatory triggers, and steroid resistance (1, 2). The marked variability in the individual 
responses to FP suggest that some children in the difficult-to-treat group did respond well to ICS 
while others were resistant. The lack of any association between the steroid regulated genes and 
asthma control is also a concern. Analysis of the outcome variables was undertaken separately. A 
combined analysis may have been informative and may have identified individual children who 
truly steroid resistant. 
 
So where does that leave the assessment of steroid resistance in children with severe asthma? Any 
test of steroid resistance would need to be useful for individual children and not simply show group 
differences. The data presented by Goleva et al (9), together with earlier studies (7,8) do suggest 
that studies of the mechanism(s) underlying steroid resistance will be informative, but we clearly 
have a long way to go before a “clinic-ready” test will be available. In the meantime, we must rely 
on clinical first principles. As the vast majority of children with asthma will be controlled by low 
dose ICS, this is the place to start. For children who do not come under control within a short 
period, say one month, further assessment is warranted. This should include: re-visiting the 
diagnosis – does the child have asthma?; examining inhaler/spacer technique; addressing 
medication adherence; and if control is poor, additional therapy. Some children will continue to 
receive high dose steroids, with the associated adverse effects when they are not able to respond. At 
this time, there is no easy way to tell who these children are. 
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Figure 1: Schematic representation of the total study population (Pongracic et al (6), the sub-
population reported by Goleva et al. (9) and the study outcomes. FP = fluticasone propionate. 
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